ACYCLOVIR

Search structure
Trade Names:
Synonyms:
Status: Approved (1982)
Entry Type: Small molecule
Molecule Category: Parent Prodrug
UNII: X4HES1O11F

Structure
InChI Key MKUXAQIIEYXACX-UHFFFAOYSA-N
Smile Nc1nc(O)c2ncn(COCCO)c2n1
InChI
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

Physicochemical Descriptors

Property Name Value
Molecular Formula C8H11N5O3
Molecular Weight 225.21
AlogP -0.92
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 4.0
Polar Surface Area 119.31
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 16.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human herpesvirus 1 DNA polymerase inhibitor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - -
Enzyme Transferase
- 1000000 12589.25 100-180000 37
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -24.99--1.46
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - -2-105.48
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - -

Metabolites

visNetwork

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Herpes Labialis 4 D006560 ClinicalTrials
Cytomegalovirus Infections 3 D003586 ClinicalTrials
HIV Infections 3 D015658 ClinicalTrials

Related Entries

MCS

Scaffolds

Salt
Mixture

Side Effects from Label

Side effects Relative Frequency (%) Labels
General disorders and administration site conditions Discomfort 11.5
General disorders and administration site conditions Feeling abnormal 11.5
General disorders and administration site conditions Ill-defined disorder 11.5
General disorders and administration site conditions Malaise 11.5
Gastrointestinal disorders Nausea
General disorders and administration site conditions Discomfort
General disorders and administration site conditions Discomfort 11.1
General disorders and administration site conditions Feeling abnormal
General disorders and administration site conditions Feeling abnormal 11.1
Nervous system disorders Headache
General disorders and administration site conditions Ill-defined disorder
General disorders and administration site conditions Ill-defined disorder 11.1
General disorders and administration site conditions Malaise
General disorders and administration site conditions Malaise 11.1
Gastrointestinal disorders Nausea 8.0
Gastrointestinal disorders Vomiting 8.0
Nervous system disorders Headache 5.9
Gastrointestinal disorders Diarrhoea 5.0
Gastrointestinal disorders Nausea 4.8
Investigations Body temperature increased 4.0
Gastrointestinal disorders Diarrhoea 3.2
Gastrointestinal disorders Diarrhoea 2.7
Gastrointestinal disorders Vomiting
Gastrointestinal disorders Vomiting 2.5
Gastrointestinal disorders Diarrhoea 2.4
Gastrointestinal disorders Nausea 2.4
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Diarrhoea 2.2
Nervous system disorders Headache 2.2
Metabolism and nutrition disorders Dehydration 2.0
Infections and infestations Herpes simplex 2.0
Infections and infestations Nasopharyngitis 2.0
Respiratory, thoracic and mediastinal disorders Rhinorrhoea 2.0
Nervous system disorders Headache 1.9
Skin and subcutaneous tissue disorders Dermatitis 1.7
Skin and subcutaneous tissue disorders Rash 1.7
Gastrointestinal disorders Diarrhoea 1.5
Nervous system disorders Headache 1.5
Skin and subcutaneous tissue disorders Dermatitis 1.3
Skin and subcutaneous tissue disorders Rash 1.3
General disorders and administration site conditions Asthenia 1.2
Nervous system disorders Paraesthesia 1.2
Nervous system disorders Headache 0.9
Nervous system disorders Paraesthesia 0.8
Gastrointestinal disorders Diarrhoea

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
15.49
General disorders and administration site conditions
11.41
Skin and subcutaneous tissue disorders
8.03
Injury, poisoning and procedural complications
7.73
Psychiatric disorders
7.02
Gastrointestinal disorders
6.07
Investigations
5.28
Renal and urinary disorders
5.2
Infections and infestations
5.13
Vascular disorders
4.11
Immune system disorders
3.6
Respiratory, thoracic and mediastinal disorders
3.29
Cardiac disorders
2.67
Musculoskeletal and connective tissue disorders
2.5
Eye disorders
2.41
Blood and lymphatic system disorders
2.14
Metabolism and nutrition disorders
2.06

Cross References

Resources Reference
CAS NUMBER 59277-89-3
ChEBI 2453
ChEMBL CHEMBL184
DrugBank DB00787
DrugCentral 85
EPA CompTox DTXSID1022556
FDA SRS X4HES1O11F
Human Metabolome Database HMDB14925
Guide to Pharmacology 4829
KEGG C06810
PDB AC2
PharmGKB PA448045
PubChem 2022
SureChEMBL SCHEMBL3175
ZINC ZINC000001530555
CONTENTS